Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 2/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15061243 | 0.86 | NAMPT (0.40) | GLSSCDNAMPTCKS1BSKP1 | |
| SCHEMBL381069 | 0.84 | F13A1 (0.41) | GLSSCDNAMPTHDAC1 | |
| SCHEMBL381658 | 0.83 | PAX8 (0.38) | GLS | |
| SCHEMBL381068 | 0.80 | ATM (0.41) | GLSSCDCTSKCTSLCTSB | |
| SCHEMBL15061244 | 0.79 | HDAC3 (0.41) | NAMPTCKS1BSKP1SKP2HDAC3 | |
| SCHEMBL381398 | 0.78 | CNR1 (0.41) | — | |
| SCHEMBL20934803 | 0.74 | NAMPT (0.47) | NAMPTHDAC3HDAC8 | |
| SCHEMBL5153340 | 0.70 | NAMPT (0.50) | NAMPT | |
| SCHEMBL29929054 | 0.70 | P4HTM (0.54) | NAMPT | |
| SCHEMBL1734048 | 0.70 | P4HTM (0.54) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2409977-A1 | AMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | GLS 2376/4885SCD 3646/4885NAMPT 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.